Parisa Emami Naeini, MD
Ophthalmology · Sacramento, CANPI 1689921363
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $39,660 of the $59,372 with a category attached, or 66.8%. 11 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 35.1% of the total. Among ophthalmology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 64 payments — averaging $927.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$21K
- Genentech USA, Inc.$17K
- Genentech, Inc.$8K
- AbbVie$7K
- Eyepoint US, Inc.$3K
- Alimera Sciences, Inc.$2K
- plus $2K from 5 others
Across 21 payments — averaging $9316.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$164K
- F. Hoffmann-la Roche AG$19K
- Eyepoint US, Inc.$13K
What the payments were for
- Consulting fees$39,66067%
- Speaking & faculty fees$12,80922%
- Travel & lodging$3,6656%
- Food & beverage$3,2375%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 27 | $20,841 |
| Genentech USA, Inc. | 13 | $16,504 |
| Genentech, Inc. | 2 | $7,807 |
| AbbVie | 3 | $7,038 |
| Eyepoint US, Inc. | 3 | $3,387 |
| Alimera Sciences, Inc. | 2 | $1,946 |
| Dutch Ophthalmic, USA | 1 | $840 |
| Regeneron | 10 | $485 |
| Alcon Research LLC | 1 | $300 |
| Harrow Eye, LLC | 1 | $115 |
| Novartis | 1 | $110 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XIPERE$20,109
- VABYSMO$7,928
- YUTIQ$3,387
- Iluvien$1,850
- EVA, combined machine$840
- TISSUEBLUE$840
- OZURDEX$600
- VYZULTA$261
- MIEBO$149
- XIIDRA$149
- enVista MX60 IOL$149
- STELLARIS ELITE$149
- LOTEMAX SM$111
- PROLENSA$111
- BEOVU$110
How this compares
$59,372 in reported general payments places this provider in the 95th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 23 | $833 |
| Latanoprost | 11 | $420 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 12 | $198 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Sacramento
- Richard LewisSacramento$262K
- Samuel LeeSacramento$200K
- Daniel SchwartzSan Francisco$8M
- Michael BerlinWest Hollywood$5.7M
- Gilbert KlimanMenlo Park$1.5M
- Kuldev SinghStanford$1.5M
- Raymond DouglasBeverly Hills$1.3M
- John AffeldtLoma Linda$1.1M
- Srinivas SaddaPasadena$1M
- Sheri RowenNewport Beach$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.